World's Best Scientists 2026 revealed!
Award Badge
Medicine
Italy
2023

D-Index & Metrics

Medicine

D-Index
147
Citations
99625
World Ranking
1262
National Ranking
28

Aron Goldhirsch publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Aron Goldhirsch sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 848 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Aron Goldhirsch D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Aron Goldhirsch sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 147 D-Index — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Italy Leader Award

Overview

Aron Goldhirsch was affiliated with the European Institute of Oncology in Italy. Their research primarily focused on medicine with a significant emphasis on oncology and cancer research. Their work contributed to multiple subfields including oncology, cancer research, pulmonary and respiratory medicine, genetics, and public health, environmental, and occupational health.

The scientist's main topics of investigation included:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • Estrogen and related hormone effects
  • Cancer Risks and Factors
  • Reproductive Biology and Fertility
  • Cancer survivorship and care
  • Cancer Genomics and Diagnostics

Among their recent published papers were:

  • "Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer," 2023, New England Journal of Medicine
  • "Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials," 2022, Journal of Clinical Oncology
  • "Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion," 2021, Clinical Cancer Research
  • "Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D," 2022, The Breast
  • "Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy," 2021, The Breast

Goldhirsch published frequently in specific scientific venues including:

  • The Breast
  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Cancer Research

Collaborations were a notable part of their academic output. Frequent co-authors included:

  • Marco Colleoni
  • Richard D. Gelber
  • Olivia Pagani
  • Meredith M. Regan
  • Alan S. Coates

This body of work indicates a sustained engagement with breast cancer studies, focusing on treatment strategies, genetic factors influencing cancer diagnosis, hormone-related effects, and survivorship care.

Best Publications

  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

    Martine J. Piccart-Gebhart;Marion Procter;Brian Leyland-Jones;Aron Goldhirsch

  • Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

    A. Goldhirsch;W.C. Wood;A.S. Coates;R.D. Gelber

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

    Beat Thürlimann;Aparna Keshaviah;Alan S Coates

  • Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

    A. S. Coates;E. P. Winer;A. Goldhirsch;R. D. Gelber

  • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

    Ian Smith;Marion Procter;Richard D Gelber;Sébastien Guillaume

  • Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

    Aron Goldhirsch;J. N. Ingle;R. D. Gelber;A. S. Coates

  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

    José Baselga;José Baselga;Ian Bradbury;Holger Eidtmann;Serena Di Cosimo;Serena Di Cosimo

  • Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

    A. Goldhirsch;J. H. Glick;R. D. Gelber;A. S. Coates

  • Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

    Viviana Galimberti;Bernard F. Cole;Bernard F. Cole;Stefano Zurrida;Giuseppe Viale;Giuseppe Viale

  • Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007

    A. Goldhirsch;W. C. Wood;R. D. Gelber;A. S. Coates

  • Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

    Alan S. Coates;Aparna Keshaviah;Beat Thürlimann;Henning Mouridsen

  • Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

    B A Gusterson;R D Gelber;A Goldhirsch;K N Price

  • Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer

    Aron Goldhirsch;John H. Glick;Richard D. Gelber;Hans-Jörg Senn

  • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

    David Cameron;Martine J Piccart-Gebhart;Richard D Gelber;Richard D Gelber;Marion Procter

  • Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer

    Aron Goldhirsch;William C. Wood;Richard D. Gelber;Alan S. Coates

  • Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines

    G. Curigliano;D. Cardinale;T. Suter;G. Plataniotis

  • Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer

    Aron Goldhirsch;John H. Glick;Richard D. Gelber;Alan S. Coates

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update

    Manfred Kaufmann;Gabriel N. Hortobagyi;Aron Goldhirsch;Suzy Scholl

Frequent Co-Authors

Richard D. Gelber
Richard D. Gelber Harvard University
Giuseppe Viale
Giuseppe Viale University of Milan
Marco Colleoni
Marco Colleoni European Institute of Oncology
Alan S. Coates
Alan S. Coates University of Sydney
Karen N. Price
Karen N. Price Frontier Science Foundation
Vincenzo Bagnardi
Vincenzo Bagnardi University of Milano-Bicocca
Paolo Veronesi
Paolo Veronesi European Institute of Oncology
Meredith M. Regan
Meredith M. Regan Harvard University
Giuseppe Curigliano
Giuseppe Curigliano University of Milan
Nicole Rotmensz
Nicole Rotmensz European Institute of Oncology

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers outside of the traditional medicine route, there are several flexible online pathways to consider. Programs such as direct entry msn programs for non-nurses online offer a fast-track for individuals with a non-nursing background to enter advanced nursing fields. These programs are designed for career changers and typically emphasize a streamlined curriculum.

If you’re seeking nursing schools with more accessible admission criteria, a number of easy nursing programs to get into can help you start your journey in the healthcare sector. Many schools also offer LPN programs with no entrance exam requirements; you can learn more about these options at lpn program no entrance exam.

If you’re looking for administrative roles in healthcare, consider training at medical billing and coding schools that accept financial aid. These programs prepare you for essential support roles in medical offices and hospitals, with flexible online learning and financial support options.

Best Scientists Citing Aron Goldhirsch

Recently Published Articles